Genmab (Otc) ( (GMAB) ) has released its Q4 earnings. Here is a breakdown of the information Genmab (Otc) presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Genmab, a leading biotechnology company, focuses on developing innovative antibody-based therapeutics primarily targeting cancer and other severe diseases. Founded in 1999, it has grown into a prominent player in the industry with a strong emphasis on research and development of novel treatments.
In its 2024 annual report, Genmab celebrated its 25th anniversary, highlighting significant milestones such as the acquisition of ProfoundBio and the advancement of its proprietary technologies and late-stage clinical programs. The company reported robust financial growth and strategic expansions in its product pipeline, positioning itself for future success.
Key financial achievements included a revenue increase to DKK 21,526 million, driven by strong sales of its medicines EPKINLY and Tivdak. The acquisition of ProfoundBio added valuable assets and technologies to Genmab’s portfolio, enhancing its long-term growth potential. The company also achieved several regulatory approvals in major markets, further expanding its global reach.
Looking forward, Genmab anticipates continued revenue growth in 2025, fueled by increased royalties and product sales. The company remains committed to its vision of becoming a fully integrated biotech powerhouse by 2030, with ongoing investments in late-stage programs and strategic collaborations to drive innovation and patient impact.
